Stockscreener 앱 받기
193.06
1.34%
-2.74
Resmed Inc 주식(RMD)의 최신 뉴스
ResMed stock steadies as sleep apnea demand supports earnings growth - Ad-hoc-news.de
ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says - Moomoo
BetterInvesting™ Magazine Update on Broadridge Financial Resources Inc. (NYSE:BR) and ResMed Inc. (NYSE - marketscreener.com
ResMed stock trades near record territory as sleep apnea demand drives revenue growth - Ad-hoc-news.de
UBS lowers ResMed stock price target to $300 on valuation - Investing.com UK
UBS lowers ResMed stock price target to $300 on valuation By Investing.com - Investing.com Nigeria
ResMed stock trades near recent highs as sleep apnea demand supports growth - Ad-hoc-news.de
Can ResMed (ASX:RMD) Reignite Growth by Slimming Down? - Kalkine Media
ResMed sharpens focus with a strategic sale: The Shift Few Are Watching - Kalkine Media
ResMed Target Price Cut 10% to A$40.00/Share by Canaccord Genuity>RMD.AU - Moomoo
Daily Brief Health Care: Personalis Inc, ResMed Inc, Ascentage Pharma, Apnimed, UltraGreen.ai, Horizon Quantum Holdings, Scribe Therapeutics and more - Smartkarma
Daily Brief Australia: EQ Resources, ResMed Inc, BHP Group Ltd and more - Smartkarma
RMD stock holds after latest ResMed results - ad-hoc-news.de
ResMed stock steadies as investors weigh obesity drug impact and solid earnings base - Ad-hoc-news.de
ResMed stock steadies as investors weigh growth and margins after recent quarterly update - ad-hoc-news.de
ResMed stock trades steady as sleep apnea demand supports earnings - ad-hoc-news.de
ResMed Inc. stock falls Friday, underperforms market - MarketWatch
Is ResMed Stock a Buy After the Noctrix Acquisition? - TIKR.com
RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276 - Moomoo
How Investors Are Reacting To ResMed (RMD) Downgrade Amid FY27 Cost and Supply Pressures - Sahm
Resmed to sell MatrixCare business to PE firm Frazier Healthcare Partners - DOTmed
ResMed stock stabilizes as investors weigh recent growth and margin trends - ad-hoc-news.de
Morgans reaffirms Pro Medicus, backs ResMed sale, holds Worley - MSN
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed downgraded at RBC Capital Markets on FY27 challenges - MSN
Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
ResMed stock downgraded at RBC Capital Markets (RMD:NYSE) - Seeking Alpha
FDA issues early alert for certain Resmed Astral ventilators - MassDevice
How much could ResMed shares rise according to Morgans? - The Motley Fool Australia
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating - Moomoo
ResMed shares rise over 3% as $490 million MatrixCare divestment fuels buybacks - Traders Union
ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health - ChartMill
Why Is ResMed Stock Down Today? - Kalkine
Health Check: Restless investors question sleep giant Resmed’s short-term prospects - Stockhead
ResMed (ASX:RMD) Falls — What Is Behind the Medical Device Giant’s Session Decline? - Kalkine
What Puts ResMed (ASX:RMD) At The Heart Of Healthcare Reset? - Kalkine Media
ResMed Price Target Cut 1.8% to A$40.97/Share by Morgans - Moomoo
Baird Adjusts ResMed Price Target to $217 From $225, Maintains Neutral Rating - Moomoo
Morgan Stanley Maintains ResMed(RMD.US) With Hold Rating, Maintains Target Price $230 - Moomoo
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY) - The Globe and Mail
ResMed Inc. stock falls Monday, underperforms market - MarketWatch
Cleveland Medical Devices Won Favorable PTAB Outcomes In 5 Of 6 Resmed IPR Challenges - TradingView
Cleveland Medical Devices Reports Favorable PTAB Outcomes in Five of Six ResMed IPR Challenges - PR Newswire
Citi Downgrades ResMed to Neutral From Buy; Price Target Is AU$34 - Moomoo
Citigroup Downgrades ResMed to Neutral From Buy, Adjusts Price Target to $235 From $270 - Moomoo
ResMed Price Target Cut to $235.00/Share From $270.00 by Citigroup - Moomoo
ResMed Inc. (RMD) Stock Analysis: Navigating a 25.60% Potential Upside Amidst Strong Healthcare Sector Growth - DirectorsTalk Interviews
ResMed stock reflects steady demand for sleep apnea solutions - ad-hoc-news.de
Citi Downgrades ResMed to Neutral From Buy; Price Target is AU$34 - marketscreener.com
ResMed (ASX:RMD) Falls Almost 5% as Healthcare Stocks Become One of the ASX's Biggest Drags - Kalkine
ResMed Stock Sinks as Citi Sounds Supply Alarm - TipRanks
ResMed Inc. stock falls Wednesday, underperforms market - MSN
In an era of ‘baddies,’ companies are racing to keep up with the influencer economy - CNN
How Investors Are Reacting To ResMed (RMD) Selling MatrixCare To Refocus On Core Sleep Health - Sahm
ResMed (RMD) Divestiture of MatrixCare presentation Summary - Quartr
ResMed Is Maintained at Hold by Jefferies - Moomoo
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care - TradingView
Jefferies Adjusts Price Target on ResMed to $225 From $240 - marketscreener.com
ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health - Yahoo Finance
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Hold from Morgan Stanley - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Ord Minnett - The Globe and Mail
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from Macquarie - The Globe and Mail
ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
0.43%
자본화:
|
볼륨(24시간):